Binds Bacterium Or Similar Microorganism Or Component Or Product Thereof (e.g., Stretococcus, Legionella, Mycoplasma, Bacterium-associated Antigen, Exotoxin, Etc.) Patents (Class 530/388.4)
  • Patent number: 9534023
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 3, 2017
    Assignee: GE Healthcare BioProcess R&D AB
    Inventor: Sophia Hober
  • Patent number: 9156892
    Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: October 13, 2015
    Assignee: GE Healthcare Bio-Sciences Corp.
    Inventor: Sophia Hober
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150064198
    Abstract: The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Gerald W. Fischer, Luke T. Daum, Clara Jebet Sei
  • Patent number: 8946393
    Abstract: A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to Borrelia burgdorferi (B. burgdorferi) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with B. burgdorferi. Mammals that have early, intermediate or chronic B. burgdorferi infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant B. burgdorferi antigens and compositions that contain them are also provided.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: February 3, 2015
    Assignee: Cornell University
    Inventor: Bettina Wagner
  • Publication number: 20150023966
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: November 6, 2012
    Publication date: January 22, 2015
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, SAndrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainney, Cuihua GAO
  • Publication number: 20140371428
    Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating S. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.
    Type: Application
    Filed: October 30, 2012
    Publication date: December 18, 2014
    Inventors: Edward M. Schwarz, Mark A. Sullivan, John L. Daiss
  • Publication number: 20140356376
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20140356375
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20140348844
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: September 10, 2012
    Publication date: November 27, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenze, Matthew Cox
  • Publication number: 20140323698
    Abstract: The invention provides a two-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.
    Type: Application
    Filed: May 23, 2012
    Publication date: October 30, 2014
    Inventors: Didier Duthe, Laure Landric-Burtin, Benoit Mothes
  • Publication number: 20140286960
    Abstract: Compositions and methods for the treatment or prevention of Staphyloccus aureus infection in a subject are provided. Antibody compositions comprising monoclonal antibodies to alpha-hemolysin protein are also provided. The methods provide administering a composition to the subject in an amount effective to reduce or eliminate or prevent relapse S. aureus bacterial infection and/or induce an immune response to Staphylococcus aureus alpha-hemolysin.
    Type: Application
    Filed: July 27, 2012
    Publication date: September 25, 2014
    Applicant: Cangene Corporation
    Inventors: Jody Berry, Laura Saward, Robyn Cassan, Xiaobing Han, Mohammad Javad Aman, Rajan P. Adhikari, Hatice Karauzum
  • Publication number: 20140234339
    Abstract: The invention concerns a peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence is at least 88% identical to sequence SEQ ID NO:1 and wherein the second amino acid sequence is at least 88% identical to sequence SEQ ID NO: 2.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 21, 2014
    Inventors: Knut Ohlsen, Udo Lorenz, Roland E. Kontermann
  • Publication number: 20140227285
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 14, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Gullard, Ralph Minter, Steven Rust, Mladen Tomich
  • Publication number: 20140193429
    Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 10, 2014
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Robert P. Doyle, Joshua J. Lensbouer
  • Patent number: 8735554
    Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: May 27, 2014
    Assignee: Innovative Biosensors, Inc.
    Inventors: Colette Cote, Qiao-xi Zheng, Venkatakrishna Shyamala, Tom Hazel
  • Patent number: 8658386
    Abstract: Hybridoma cell lines which produce and secrete monoclonal antibodies which selectively bind to Mycobacterium avium subspecies paratuberculosis have been produced. Cells of M. avium subspecies paratuberculosis in biological samples may be detected and quantified by contacting the sample with the antibodies to form a M. avium subspecies paratuberculosis/antibody immunocomplex when M. avium subspecies paratuberculosis is present, which immunocomplex may then be detected. The monoclonal antibodies also may be incorporated into kits for the detection and quantification of M. avium subspecies paratuberculosis.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: February 25, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventor: John P. Bannantine
  • Patent number: 8653243
    Abstract: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: February 18, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jennifer Maynard, Jamie Sutherland
  • Patent number: 8648176
    Abstract: The present invention features, inter alia, compositions and methods for the treatment of cancer and infectious disease. The compositions include engineered proteins that specifically bind a metal chelate and may be bispecific. For example, the engineered proteins may bind (a) a target (e.g., a cellular protein) on a cancerous cell or a pathogen and (b) a metal chelate comprising DOTA, or an active variant thereof, and a metal ion such as a radionuclide. By virtue of the multiple binding sites, the engineered protein effectively delivers a metal chelate to a cell one wishes to destroy.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: February 11, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Kelly Davis Orcutt, Karl Dane Wittrup
  • Publication number: 20140037650
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody, such as a recombinant antibody, that binds IsdA and/or IsdB polypeptides.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 6, 2014
    Applicant: University of Chicago
    Inventors: Hwan Keun Kim, Andrea DeDent, Carla Emolo, Dominique M. Missaikas, Olaf Schneewind
  • Patent number: 8629249
    Abstract: A polypeptide, designated as “Streptococcus uberis Adhesion Molecule” (SUAM), and fragments of SUAM, prevent internalization and adherence of Streptococcus uberis and other streptococcal pathogens to cells. The SUAM polypeptide and fragments may be used diagnostically and therapeutically. Nucleic acid sequences encoding the SUAM polypeptide and fragments are included in the invention.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: January 14, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: Stephen P. Oliver, Raul A. Almeida, Douglas A. Luther, Hee-Myung Park
  • Publication number: 20140010820
    Abstract: Disclosed herein are compositions and methods for the isolation and purification of antibodies from a sample matrix. In particular, the present invention relates to compositions and methods for isolating and purifying antibodies exhibiting weak binding strength and low binding capacity for Protein A resin. In certain embodiments, the methods herein employ a kosmotropic salt solution, an affinity chromatographic step, and may include one or more additional chromatography and/or filtration steps to achieve the desired degree of purification. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein.
    Type: Application
    Filed: May 21, 2013
    Publication date: January 9, 2014
    Applicant: ABBVIE, INC.
    Inventors: Chen Wang, Susan Lacy, Randolf Huelsman
  • Patent number: 8623372
    Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: January 7, 2014
    Assignee: Valorisation-Recherche, Societe En commandite
    Inventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
  • Patent number: 8618261
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 31, 2013
    Assignee: Allergan, Inc.
    Inventors: Fernandez-Salas Ester, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Roger Aoki
  • Publication number: 20130338339
    Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 19, 2013
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Tomas Bjorkman, Bjorn Noren, Gustav Rodrigo, Jelena Vasic, Per-Mikael Aberg
  • Patent number: 8609102
    Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: December 17, 2013
    Assignee: Julius-Maximilians-Universitat
    Inventors: Knut Ohlsen, Udo Lorenz
  • Patent number: 8591899
    Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 26, 2013
    Assignee: State of Israel, Represented by Prime Minister's Office, Israel Institute for Biological Research
    Inventors: Avigdor Shafferman, Ofer Cohen, Theodor Chitlaru, Sagit Sela-Abramovich, Orit Gat
  • Patent number: 8586046
    Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: November 19, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joel Barry Baseman, Thirumalai Regasamy Kannan
  • Patent number: 8575315
    Abstract: The present invention provides compositions including antibodies that specifically bind at least one siderophore receptor polypeptide from a gram positive microbe. The present invention also provides methods of making and methods of using such compositions.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: November 5, 2013
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8563699
    Abstract: Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 22, 2013
    Inventors: Samuel Bogoch, Elenore S. Bogoch
  • Patent number: 8546093
    Abstract: The present invention relates to an antibody against a protein specifically expressed in methicillin-resistant strains of Staphylococcus aureus (MRSA), and a method and a kit for detecting MRSA. The present invention enables a fast and accurate detection of MRSA by using both a PBP2a-specific antibody for the detection of PBP2a and a Protein A-specific antibody for the detection of Protein A.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: October 1, 2013
    Assignee: Dinona Inc.
    Inventors: Hyung-Geun Song, Sang-Soon Yoon, Hae-Jung Kim, Gil-Yong Jee, Mi-Hyang Shin, Yu-Ri Moon
  • Publication number: 20130236469
    Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.
    Type: Application
    Filed: May 25, 2011
    Publication date: September 12, 2013
    Applicant: Intervacc AB
    Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
  • Publication number: 20130202618
    Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.
    Type: Application
    Filed: April 15, 2011
    Publication date: August 8, 2013
    Applicant: Progenics Pharmaceuticals, Inc.
    Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
  • Patent number: 8501182
    Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: August 6, 2013
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
  • Patent number: 8475798
    Abstract: Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: July 2, 2013
    Assignees: Inhibitex, Inc., The Texas A&M University System
    Inventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Linda Santos, Maria Bowden, Magnus Hook
  • Patent number: 8431687
    Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: April 30, 2013
    Assignee: New York University
    Inventors: Victor J. Torres, Ashley L. Dumont
  • Patent number: 8404820
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: March 26, 2013
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
  • Publication number: 20130064851
    Abstract: The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria.
    Type: Application
    Filed: November 12, 2012
    Publication date: March 14, 2013
    Applicant: VACCINE RESEARCH INTERNATIONAL PLC
    Inventor: Vaccine Research International PLC
  • Publication number: 20130045208
    Abstract: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.
    Type: Application
    Filed: April 3, 2012
    Publication date: February 21, 2013
    Applicant: Haptogen, Ltd.
    Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter
  • Patent number: 8378078
    Abstract: The invention relates to a method for in vitro seriological diagnosis of Whipple's disease, whereby the bacteria responsible for the disease are isolated and established in a culture and brought into contact with the serum or biological fluid of an infected patient. The invention also relates to useful oligonucleotides with a probe and a primer for amplifying, sequencing and detecting the gene rpoB of the bacteria, Tropheryma whippelii.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: February 19, 2013
    Assignee: Protisvalor Mediterranee
    Inventors: Didier Raoult, Bernard La Scola, Marie-Laure Birg, Florence Fenollar
  • Patent number: 8372958
    Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: February 12, 2013
    Assignee: Biosynexus Incorporated;
    Inventors: Gerald W. Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
  • Publication number: 20130035476
    Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.
    Type: Application
    Filed: September 6, 2012
    Publication date: February 7, 2013
    Applicant: THE TEXAS A & M UNIVERSITY SYSTEM
    Inventors: Magnus Hook, Ya-Ping Ko, Emanuel Smeds, Vannakambadi K. Ganesh
  • Patent number: 8349326
    Abstract: The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has one or more monomers that have a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM). Disease agents include bacteria, bacterial proteins, viruses, viral proteins, cancer cells, and proteins or toxins produced therefrom or from other sources such as snakes, insects, plants, etc.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: January 8, 2013
    Assignee: Tufts University
    Inventors: Charles B. Shoemaker, Jean Mukherjee
  • Patent number: 8337846
    Abstract: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the immunogenic polypeptides are also described.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: December 25, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Martina Ochs, Roger Brookes, Robert Charlebois, Jeremy Yethon
  • Patent number: 8324354
    Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 4, 2012
    Assignee: Stichting Dienst Landbouwkundig Onderzoek
    Inventor: Hilda Elizabeth Smith
  • Patent number: 8318908
    Abstract: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: November 27, 2012
    Assignee: Intercell AG
    Inventors: Dieter J. Reinscheid, Heike Boisvert, Axel Schubert, Bernhard J. Eikmanns, Andreas Meinke
  • Patent number: 8309090
    Abstract: Isolated monoclonal antibodies that bind and/or neutralize anthrax protective antigen (PA) are disclosed as well as hybridomas secreting such antibodies. The invention also provides anti-PA fragments of the antibodies of the invention and recombinantly produced antibodies. Also provided are pharmaceutical compositions containing the antibodies or antibody fragments and uses and methods involving same.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: November 13, 2012
    Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National Defense
    Inventor: Wei-Gang Hu
  • Publication number: 20120282274
    Abstract: The disclosure provides specific and sensitive anti-toxin B antibodies and fragments thereof suitable for diagnosing Clostridium difficile infection. The antibodies and fragments recognize an epitope in the C-terminal 250-amino-acid region of toxin B of C. difficile, including epitopes defined by protein repeat sequences in this region of toxin B. This disclosure also provides the toxin B-specific epitope in the C-terminal 250-amino-acid region of toxin B of C. difficile for use in vaccine development as well as in the treatment of CDI disease and in treatment of the relapse of CDI disease. Also provided are toxin B polypeptides lacking the cytotoxic domain useful in treating or preventing CDI disease. PCR-based diagnostic assays targeting the 750-nucleotide region at the 3? end of tcdB are also provided.
    Type: Application
    Filed: November 22, 2010
    Publication date: November 8, 2012
    Applicant: NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTE
    Inventors: Jian-Ping Jin, Lance R. Peterson
  • Patent number: 8268316
    Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 18, 2012
    Assignee: Aprogen, Inc
    Inventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
  • Patent number: 8263078
    Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: September 11, 2012
    Assignees: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.
    Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy